Our findings have important implications for clinical management of PCa with RTK and tyrosine kinase inhibitors (TKIs) and provide a potential rational explanation for the disappointing single‐agent activity of EGFR inhibitors (erlotinib, gefitinib), SRC inhibitors (dasatinib, KX2‐391, saracatinib) as well as anti‐HER2‐targeted antibody therapeutics (pertuzumab, trastuzumab) in PCa clinical trials despite strong preclinical evidence for a role of these targets in PCa (Solit & Rosen, 2007; Gallick et al, 2012). The gene discussed is SRC; the disease is posterior cortical atrophy.